Bristol-Myers Squibb Company

Location

New Jersey

Founded

1887-04-10

Risk Signals

10468 news mentions monitored

Industry Context

This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.

Recent Articles about Bristol-Myers Squibb Company

Live alerts from global media, monitored by Business Radar

Abecma clocks $164m for Bristol-Myers but supply constraints remain Abecma clocks $164m for Bristol-Myers but supply constraints remain Abecma clocks $164m for Bristol-Myers but supply constraints remain

2025-03-15 (bioprocessintl.com)

Abecma clocks $164m for Bristol-Myers but supply constraints remain Abecma clocks $164m for Bristol-Myers but supply constraints remain Abecma clocks $164m for Bristol-Myers but supply constraints remain

Bristol-Myers Squibb says it expects viral vector supply to ramp up later in the year as third-party and inhouse capacity come online.

Read more
Bristol-Myers Squibb stock drops 6% after FDA delays approval deadline for cancer drug

2018-10-22 (marketwatch.com)

Bristol-Myers Squibb stock drops 6% after FDA delays approval deadline for cancer drug

Bristol-Myers Squibb Co. undefined shares dropped nearly 6% in extremely heavy Monday morning trade after the company said that, because of new information...

Read more
Bristol-Myers Squibb stock drops 6% after FDA delays approval deadline for cancer drug

2018-10-22 (marketwatch.com)

Bristol-Myers Squibb stock drops 6% after FDA delays approval deadline for cancer drug

Bristol-Myers Squibb Co. undefined shares dropped nearly 6% in extremely heavy Monday morning trade after the company said that, because of new information...

Read more
FDA Delays Decision on BMS, 2seventy bio’s Push for Earlier Line Abecma Treatment

(biospace.com)

FDA Delays Decision on BMS, 2seventy bio’s Push for Earlier Line Abecma Treatment

The regulator has decided to hold an advisory committee meeting regarding BMS and 2seventy bio’s bid to move the CAR-T cell therapy into earlier lines of treatment, missing its previous target action date of Dec. 16.

Read more
FDA Delays Decision on BMS, 2seventy bio’s Push for Earlier Line Abecma Treatment

(biospace.com)

FDA Delays Decision on BMS, 2seventy bio’s Push for Earlier Line Abecma Treatment

The regulator has decided to hold an advisory committee meeting regarding BMS and 2seventy bio’s bid to move the CAR-T cell therapy into earlier lines of treatment, missing its previous target action date of Dec. 16.

Read more
FDA Delays Decision on BMS, 2seventy bio’s Push for Earlier Line Abecma Treatment

(biospace.com)

FDA Delays Decision on BMS, 2seventy bio’s Push for Earlier Line Abecma Treatment

The regulator has decided to hold an advisory committee meeting regarding BMS and 2seventy bio’s bid to move the CAR-T cell therapy into earlier lines of treatment, missing its previous target action date of Dec. 16.

Read more
BeiGene's supply of Bristol Myers Squibb's Abraxane freezes in China amid Fresenius Kabi plant woes

(fiercepharma.com)

BeiGene's supply of Bristol Myers Squibb's Abraxane freezes in China amid Fresenius Kabi plant woes

It’s not very often you hear about manufacturing problems at Western facilities slammed by Chinese authorities. | It’s not very often you hear about manufacturing problems at Western facilities slammed by Chinese authorities. But it just happened. Due to breaches found at a Fresenius Kabi site in the U.S., Bristol Myers' Abraxane supply to BeiGene in China has been put to an abrupt halt, threatening a $100-million-a-year business.

Read more

Never miss a headline about Bristol-Myers Squibb Company

Set up smart alerts with Business Radar and receive real-time updates on any new risk signal or major news story.

  • ✔️ Used by 100+ compliance teams and analysts
  • ✔️ Covers 154M+ sources in 40+ languages